Lithium

Introduction Overview

Generic Name

lithium

Brand Name

Lithobid, Eskalith, Lithonate, Lithotabs, Eskalith-CR

Dosage Form

oral tablets and extended-release tablets

Drug Class

Antimanic agents

Pharmacokinetics

Absorption: Lithium is well absorbed from the gastrointestinal tract, primarily the stomach and small intestine, reaching peak plasma concentrations within 1 to 3 hours after administration of immediate-release formulations and approximately 4 to 5 hours after extended-release formulations. Its bioavailability is generally high and consistent. Food intake can slightly delay absorption but does not significantly affect the extent of absorption. Absorption kinetics are linear within therapeutic dosing ranges. Distribution: After absorption, lithium distributes rapidly throughout total body water with no significant binding to plasma proteins, and it does not accumulate in fat tissues. Its volume of distribution ranges between 0.6 to 0.9 L/kg, approximating total body water. Lithium crosses the blood-brain barrier slowly and achieves cerebrospinal fluid concentrations about 40–50% of plasma levels after repeated dosing. It also crosses the placenta and is distributed in breast milk. Metabolism: Lithium is unique among psychotropic medications in that it is not metabolized by the liver or other tissues. It exists as a simple monovalent cation (Li+) and circulates unchanged in plasma. This lack of metabolism eliminates hepatic drug-drug interactions but necessitates reliance on renal clearance for elimination. Elimination: Lithium is almost exclusively eliminated by the kidneys through glomerular filtration. Approximately 80% of the filtered lithium is reabsorbed in the proximal tubules, mirroring sodium reabsorption mechanisms. Renal clearance ranges between 10-40 mL/min, leading to a biological half-life of about 18 to 36 hours in adults; this may be prolonged in elderly populations and in states of renal impairment. Factors affecting renal function or sodium balance (such as dehydration, diuretics, NSAIDs) can significantly alter lithium elimination and precipitate toxicity. Regular monitoring of serum lithium levels and renal function is essential during therapy to avoid toxicity and maintain therapeutic effectiveness.

Dosage Forms

Available Dosage Forms: Lithium is available primarily as oral tablets, including immediate-release and extended-release formulations. Brand names offering these tablets include Lithobid, Eskalith, Eskalith-CR, Lithonate, and Lithotabs. These tablets come in varied strengths including 150 mg, 300 mg, and 600 mg, with extended-release tablets often available as 300 mg. While lithium is also available in capsule and oral liquid formulations, the commercially predominant forms are tablets. Dosages for Adults and Adolescents: The usual adult dose for acute management of mania or bipolar disorder typically begins at 1800 mg/day, administered as 600 mg three times daily for immediate-release tablets or 900 mg twice daily for extended-release tablets. Maintenance doses usually range from 900 to 1200 mg/day, divided accordingly. Pediatric dosing for patients 12 years and older generally parallels adult dosing with careful titration and monitoring. Specific Patient Populations: Dose adjustments are crucial in elderly patients due to decreased renal clearance and increased sensitivity. Initiation in children under 12 years is uncommon and off-label. Dosing must be cautiously managed in patients with renal impairment, cardiovascular disease, or thyroid disorders. Regular therapeutic drug monitoring is mandatory to customize dosing and minimize toxicity risks in these populations. Clinical monitoring includes serum lithium levels, renal, thyroid, and electrolyte assessments.

Mechanism Of Action

Lithium acts primarily at the cellular level by modulating the flow of sodium ions through nerve and muscle cells. This regulation of sodium ion transport influences neuronal excitability and neurotransmitter release, which is critical in the management of mania and bipolar disorder. At the molecular level, lithium inhibits several intracellular enzymes, notably inositol monophosphatase (IMPase), leading to modulation of the phosphatidylinositol signaling pathway. This inhibition decreases the recycling of inositol, thereby altering second messenger systems that affect neurotransmission and neuronal plasticity. Lithium also influences glycogen synthase kinase 3-beta (GSK-3β), a key regulatory enzyme involved in cellular processes including apoptosis, gene expression, and neuroprotection. By inhibiting GSK-3β, lithium promotes neurotrophic and neuroprotective effects, which may contribute to its mood-stabilizing properties and potential benefits in neurodegenerative disorders. Clinically, these mechanisms culminate in the stabilization of mood by reducing the frequency and severity of manic episodes and preventing recurrence. Compared with other mood stabilizers such as valproate or carbamazepine, lithium uniquely exerts neuroprotective effects via GSK-3β inhibition and intracellular signaling modulation, which have been supported by extensive clinical trials demonstrating efficacy in bipolar disorder management. Furthermore, lithium's modulation of glutamatergic and dopaminergic neurotransmission impacts neural circuitry relevant to mood regulation. Ongoing research continues to elucidate lithium's multifaceted biochemical interactions and its potential expanded therapeutic roles beyond mood stabilization.

Pharmacological Actions

Mood stabilization by modulating neuronal excitability and intracellular signaling.
Blockade of inositol monophosphatase leading to decreased phosphatidylinositol turnover.
Inhibition of glycogen synthase kinase 3-beta, promoting neuroprotection and neurogenesis.
Regulation of sodium ion transport across nerve and muscle cells affecting nerve signal transmission.
Reduction of hyperexcitability linked to manic episodes.
Neuroprotective effects potentially beneficial in neurodegenerative diseases.
Modulation of neurotransmitters including glutamate and dopamine.
Prevention and attenuation of manic episodes in bipolar disorder.
No hepatic metabolism with renal elimination ensuring minimal pharmacokinetic interactions.
Stabilization of intracellular signaling pathways implicated in mood disorders.
Influence on circadian rhythms relevant to bipolar disorder pathology.
Reduction of suicide risk in patients with mood disorders.
Improvement of neuronal resilience through modulation of apoptotic pathways.
Potential anti-inflammatory effects within the central nervous system.

Therapeutic Or Clinical Uses

Treatment of acute manic episodes in bipolar disorder.
Maintenance therapy to prevent recurrence of mania and bipolar mood episodes.
Mood stabilization in patients exhibiting manic or mixed bipolar disorder symptoms.
Management of recurrent bipolar depression adjunctively.
Off-label uses in augmentation therapy for treatment-resistant depression.
Treatment of certain cluster headache syndromes as a prophylactic measure.
Reduction of suicide risk in patients with mood disorders.
Adjunctive therapy in schizoaffective disorder with manic features.
Neuroprotective investigational use in neurodegenerative diseases.
Use in pediatric patients aged 12 years and older for bipolar mania management.
Occasionally employed in augmentation for aggressive or impulsive behaviors.
Potential investigational uses in traumatic brain injury recovery protocols.
Treatment of cyclic mood disorders and cyclothymia.
An alternative therapy in lithium-respondent patients where other mood stabilizers fail.
Clinical trial participation in novel neuropsychiatric disorder management.

Side Or Adverse Effects

Lithium toxicity characterized by muscle weakness, twitching, drowsiness, confusion, and seizures.
Tremors, often fine and hand-specific, common with chronic use.
Gastrointestinal upset including nausea, vomiting, and loss of appetite.
Polyuria and polydipsia due to nephrogenic diabetes insipidus.
Cognitive impairment manifesting as slowed thinking or memory problems.
Thyroid dysfunction, including hypothyroidism and rarely hyperthyroidism.
Weight gain associated with long-term therapy.
Skin reactions such as rash and acneiform eruptions.
Edema and fluid retention especially in susceptible patients.
Cardiac arrhythmias, including bradycardia and prolonged QT interval in rare cases.
Blurred vision and ocular disturbances.
Headache and dizziness, which may impair coordination.
Fatigue and generalized weakness.
Increased risk of renal impairment with long-term use.
Serotonin syndrome when combined with serotonergic drugs.

Precautions

Monitor serum lithium concentrations regularly to maintain therapeutic window.
Avoid dehydration; maintain adequate hydration during therapy.
Use cautiously in patients with renal or cardiovascular disease.
Evaluate thyroid and renal function prior to and during therapy.
Be vigilant for signs of lithium toxicity, especially with dose adjustments or illness.
Avoid abrupt discontinuation due to risk of relapse.
Adjust dose carefully in elderly patients and those with impaired renal function.
Avoid concurrent use with medications altering renal lithium clearance without close monitoring.
Counsel patients regarding consistent dietary sodium intake to prevent fluctuations in lithium levels.
Pregnancy category D: use only if benefits outweigh risks; effective contraception recommended.
Not recommended during breastfeeding due to excretion in milk and potential infant exposure.
Use with caution in patients with neurological disorders or seizure history.
Avoid activities requiring mental alertness until individual response is known.
Precaution during febrile illnesses, vomiting, or diarrhea that may predispose to toxicity.
Periodic ECG monitoring recommended in patients with cardiac risk factors.

Warnings

Lithium has a narrow therapeutic index with potential for fatal toxicity.
Monitor for signs of lithium overdose such as severe tremors, confusion, seizures, and arrhythmias.
Not to be used during pregnancy without thorough risk assessment due to teratogenicity.
Avoid dehydration and electrolyte imbalances which can precipitate toxicity.
Extended-release tablets must be swallowed whole to avoid dose dumping and toxicity.
Serotonin syndrome risk when combined with serotonergic or MAO inhibitors.
Require frequent laboratory monitoring during initiation and maintenance phases.
Risk of exacerbation of renal impairment requiring dose adjustment or discontinuation.
Dangerous to self-medicate or adjust doses without medical supervision.
Lithium toxicity may manifest with subtle neuropsychiatric symptoms before systemic signs.
Avoid use in patients with known hypersensitivity to lithium salts.
Careful management required during intercurrent illnesses such as fever or gastrointestinal upset.
Risk of increased intracranial pressure requiring urgent evaluation if symptoms emerge.
Concomitant use with diuretics, NSAIDs, or ACE inhibitors increases risk of toxicity.
Warning about interference with thyroid function necessitating periodic assessment.

Contraindication

Known hypersensitivity or allergy to lithium or any component of the formulation.
Severe renal impairment or significant renal disease due to impaired lithium clearance.
Significant cardiovascular disease including arrhythmias and conduction defects.
Severe dehydration or electrolyte imbalances not corrected prior to initiation.
Patients under 7 years of age due to insufficient safety data.
Concomitant use of drugs that contraindicate lithium (such as certain diuretics) without close monitoring.
Severe thyroid disease untreated or unstable at start of therapy.
History of lithium toxicity or overdose without definitive resolution.
Pregnancy unless clearly benefit outweighs risk; contraindicated in first trimester unless necessary.
Conditions predisposing to sodium imbalance affecting lithium pharmacokinetics.
Severe neurological disorders where lithium may exacerbate symptoms.
Concomitant use of monoamine oxidase inhibitors without strict medical supervision.
Acute intoxication with psychoactive substances needing emergent intervention.
Patients unable to comply with strict monitoring or dosing regimen.
Concurrent serious infections leading to altered drug handling.

Drug Interactions

Diuretics (especially thiazides) increase lithium serum levels by reducing renal clearance.
Nonsteroidal anti-inflammatory drugs (NSAIDs) decrease renal lithium clearance leading to toxicity.
ACE inhibitors and angiotensin receptor blockers increase lithium levels and toxicity risk.
Antipsychotics and antidepressants increase risk of neurotoxicity and serotonin syndrome.
MAO inhibitors (e.g., isocarboxazid, phenelzine) increase serotonin syndrome risk.
Triptans and buspirone may potentiate serotonergic adverse effects.
St. John's wort and tryptophan can increase risk of serotonin syndrome.
Fentanyl and tramadol interact by increasing CNS adverse effects.
Concurrent use with other nephrotoxic agents enhances risk of renal damage.
Drugs affecting electrolyte balance, such as laxatives, can alter lithium concentration.
Caffeine and theophylline may reduce lithium levels by increasing renal clearance.
Sodium bicarbonate supplementation can decrease lithium reabsorption, lowering levels.
Herbal products with diuretic or hypertensive effects may unpredictably alter lithium kinetics.
Concurrent use with anticholinergics may decrease lithium renal clearance.
Drugs prolonging QT interval combined with lithium warrant cardiac monitoring.

Preparations Of The Drug

Lithium carbonate immediate-release tablets in strengths of 150 mg, 300 mg, and 600 mg.
Lithium carbonate extended-release tablets (e.g., Eskalith-CR, Lithobid) typically 300 mg per tablet.
Oral lithium citrate solution, used less commonly; dosing requires precise volume measurement.
Capsules available under some brands like Lithonate and Lithotabs in standard doses.
Formulations intended for oral administration only; no approved parenteral forms.
Tablets designed to be swallowed whole; do not crush or chew extended-release preparations.
Dosing devices such as calibrated syringes provided with liquid formulations.
Packaging includes medication guides detailing narrow therapeutic index and toxicity risks.
Storage recommendations: store at controlled room temperature away from moisture and heat.
Units and dosing vary; careful attention to brand and release formulation essential.
Generic lithium carbonate tablets widely available as cost-effective alternatives.
Patient counseling materials included with prescription to guide administration and monitoring.
Some brands incorporate film coating to aid swallowability and gastric tolerability.
Lot-specific assay and dissolution testing ensure consistency and bioequivalence.
Typical prescription formats include 30, 60, or 90-day supplies to allow close monitoring.